



September 7, 2016

## **Innoviva to Present at Morgan Stanley Global Healthcare Conference and Rodman & Renshaw 19th Annual Global Investment Conference**

BRISBANE, Calif.--(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ:INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will be presenting at two conferences in New York on Tuesday, September 13. The details are as follows:

Rodman & Renshaw 18<sup>th</sup> Annual Global Investment Conference  
New York Palace Hotel  
Tuesday, September 13, 9:10 a.m. EDT  
Webcast Link (archived for 90 days): [Rodman Innoviva Webcast](#)

Morgan Stanley Global Healthcare Conference  
Tuesday, September 13 at 2:55 p.m. EDT  
Grand Hyatt Hotel  
Webcast (archived for 90 days): [Morgan Stanley Innoviva Webcast](#)

### **About Innoviva**

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Innoviva's website at [www.inva.com](http://www.inva.com).

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20160907005658/en/>

Innoviva  
Eric d'Esparbes, 650-238-9640  
Senior Vice President and Chief Financial Officer  
[investor.relations@inva.com](mailto:investor.relations@inva.com)

Source: Innoviva

News Provided by Acquire Media